Results 111 to 120 of about 385 (131)

Aficamten: First Approval

Drugs
openaire   +1 more source

Aficamten and the Future of Obstructive Hypertrophic Cardiomyopathy Management

JACC
openaire   +2 more sources

Aficamten reduces cardiac contractility by modifying the actomyosin interaction

Nature Cardiovascular Research
Farid Moussavi-Harami, Michael Regnier
openaire   +1 more source

Auch Aficamten (Myosininhibitor) hocheffektiv und sicher bei HOCM

Aktuelle Kardiologie, 2023
openaire   +1 more source

Aficamten reduces symptoms in obstructive hypertrophic cardiomyopathy

Nature Reviews Cardiology
openaire   +2 more sources

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
Matthew Lee, Michael Nassif, Pablo García-Pavía   +2 more
exaly  

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
Sheila Hegde, Michael Nassif, Ahmad Masri   +2 more
exaly  

Aficamten for Obstructive Hypertrophic Cardiomyopathy. Reply.

The New England journal of medicine
Martin S, Maron, Caroline J, Coats, Daniel L, Jacoby   +2 more
openaire   +1 more source

In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor

Xenobiotica
Donghong Xu
exaly  

Aficamten Monotherapy for Hypertrophic Cardiomyopathy. Reply.

The New England journal of medicine
Pablo, Garcia-Pavia, Martin S, Maron, Gregory D, Lewis   +2 more
openaire   +1 more source